Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation siRNA therapeutics to provide better treatment options for patients worldwide.
Learn MoreArgo Biopharma specializes in siRNA drug discovery and development. Our industry-leading siRNA platform technology, RADS (RNA molecules with superior Activity, Durability, and Safety), is the cornerstone of our innovative approach.Based on this platform, the drugs have the potential to achieve the goal of one injection per year in clinical practice for certain indications.
Learn MoreAs a platform company, Argo Biopharma has a rich portfolio of product pipelines covering a wide range of indications, including cardiovascular diseases, rare diseases, CNS disorders, viral hepatitis, metabolic conditions, and more.
Learn MoreWith its cutting-edge siRNA platform technology, RADS, Argo Biopharma is able to provide Best-In-Class candidates for a range of indications.
Argo's extensive pipeline encompasses a wide range of therapeutic areas, including cardiovascular, metabolic disorders, hematological, CNS, hepatitis, and complement mediated diseases. We recognize that collaborating with other organizations can expedite the advancement of our novel medications towards clinical trials and eventual commercialization. To expand our wide pipelines, we are open to out-licensing, asset acquisitions, and strategic partnerships.
Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
Learn MoreArgo Biopharma Completes First Patient Dosing for Phase II Clinical Trial in Chronic Hepatitis B
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
Argo Biopharma Receives IND Approval for Phase II Clinical Trial of Promising siRNA-PEG-IFNα Combination Therapy in Chronic Hepatitis B
为了更好的呈现效果，移动端请竖屏浏览
